Ignite Creation Date:
2025-12-24 @ 7:58 PM
Ignite Modification Date:
2026-07-08 @ 6:25 PM
Study NCT ID:
NCT06908304
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-09-25
First Post:
2025-03-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Sponsor:
Maia Biotechnology
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Carcinoma, Non-Small -Cell Lung | View |